TY - JOUR
T1 - Melanoma central nervous system metastases
T2 - An update to approaches, challenges, and opportunities
AU - Karz, Alcida
AU - Dimitrova, Maya
AU - Kleffman, Kevin
AU - Alvarez-Breckenridge, Christopher
AU - Atkins, Michael B.
AU - Boire, Adrienne
AU - Bosenberg, Marcus
AU - Brastianos, Priscilla
AU - Cahill, Daniel P.
AU - Chen, Qing
AU - Ferguson, Sherise
AU - Forsyth, Peter
AU - Glitza Oliva, Isabella C.
AU - Goldberg, Sarah B
AU - Holmen, Sheri L.
AU - Knisely, Jonathan P.S.
AU - Merlino, Glenn
AU - Nguyen, Don X.
AU - Pacold, Michael E.
AU - Perez-Guijarro, Eva
AU - Smalley, Keiran S.M.
AU - Tawbi, Hussein A.
AU - Wen, Patrick Y.
AU - Davies, Michael A
AU - Kluger, Harriet M.
AU - Mehnert, Janice M.
AU - Hernando, Eva
N1 - Publisher Copyright:
© 2022 The Authors. Pigment Cell & Melanoma Research published by John Wiley & Sons Ltd.
PY - 2022/11
Y1 - 2022/11
N2 - Brain metastases are the most common brain malignancy. This review discusses the studies presented at the third annual meeting of the Melanoma Research Foundation in the context of other recent reports on the biology and treatment of melanoma brain metastases (MBM). Although symptomatic MBM patients were historically excluded from immunotherapy trials, efforts from clinicians and patient advocates have resulted in more inclusive and even dedicated clinical trials for MBM patients. The results of checkpoint inhibitor trials were discussed in conversation with current standards of care for MBM patients, including steroids, radiotherapy, and targeted therapy. Advances in the basic scientific understanding of MBM, including the role of astrocytes and metabolic adaptations to the brain microenvironment, are exposing new vulnerabilities which could be exploited for therapeutic purposes. Technical advances including single-cell omics and multiplex imaging are expanding our understanding of the MBM ecosystem and its response to therapy. This unprecedented level of spatial and temporal resolution is expected to dramatically advance the field in the coming years and render novel treatment approaches that might improve MBM patient outcomes.
AB - Brain metastases are the most common brain malignancy. This review discusses the studies presented at the third annual meeting of the Melanoma Research Foundation in the context of other recent reports on the biology and treatment of melanoma brain metastases (MBM). Although symptomatic MBM patients were historically excluded from immunotherapy trials, efforts from clinicians and patient advocates have resulted in more inclusive and even dedicated clinical trials for MBM patients. The results of checkpoint inhibitor trials were discussed in conversation with current standards of care for MBM patients, including steroids, radiotherapy, and targeted therapy. Advances in the basic scientific understanding of MBM, including the role of astrocytes and metabolic adaptations to the brain microenvironment, are exposing new vulnerabilities which could be exploited for therapeutic purposes. Technical advances including single-cell omics and multiplex imaging are expanding our understanding of the MBM ecosystem and its response to therapy. This unprecedented level of spatial and temporal resolution is expected to dramatically advance the field in the coming years and render novel treatment approaches that might improve MBM patient outcomes.
UR - http://www.scopus.com/inward/record.url?scp=85137218020&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85137218020&partnerID=8YFLogxK
U2 - 10.1111/pcmr.13059
DO - 10.1111/pcmr.13059
M3 - Review article
C2 - 35912544
AN - SCOPUS:85137218020
SN - 1755-1471
VL - 35
SP - 554
EP - 572
JO - Pigment Cell and Melanoma Research
JF - Pigment Cell and Melanoma Research
IS - 6
ER -